A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

NCT01821274 | Unknown Phase 1

• 1 other identifier: VEN307-DERM-002
• Study Type: interventional
• Target: 30
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of the study is to determine whether Diltiazem Hydrochloride 2% Cream will cause irritation to skin on the back of healthy volunteers after repeated application over 21-days.

Conditions

Skin Irritation

Outcome Measures

Primary Outcomes (1)

• Mean cumulative irritation score of Diltiazem Hydrochloride 2% Cream in healthy skin of humans.

  The primary variable of interest is the mean cumulative irritation score. The mean cumulative irritation score for each subject, product and site will be calculated as the sum of the irritation scores divided by the number of readings. The total cumulative irritation score for each subject and product will also be calculated as the sum of irritation scores on each of 21 evaluation days. A normalized total score for each patch will be calculated by summing the total irritation scores for all subjects, dividing by the number of readings and multiplying by 210. These parameters will be tested pairwise for product differences using Fisher's protected least significant differences in the context of the analysis of variance (ANOVA), including effects of subject and product (ie, randomized complete blocks). All pairwise differences will be tested. No adjustment for multiple comparisons will be made.

  21 days

Study Arms (4)

topical Diltiazem Hydrochloride 2% Cream

EXPERIMENTAL

0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.

Drug: Diltiazem Hydrochloride 2% Cream

Vehicle Cream

PLACEBO COMPARATOR

0.2 g applied topically under occlusive patch conditions to the infrascapular area of the back, once daily for 21 consecutive days over 3 weeks.

Drug: Vehicle Cream

0.2% sodium lauryl sulfate (SLS)

ACTIVE COMPARATOR

0.2 mL applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a positive control.

Drug: 0.1% solution o sodium lauryl sulfate (SLS)

0.9% saline

PLACEBO COMPARATOR

0.2 mL, applied topically under occlusive patch conditions to the infrascapular area of the back once daily for 21 days over 3 weeks, will serve as a negative control.

Drug: Saline 0.9%

Interventions

Diltiazem Hydrochloride 2% Cream DRUG

0.2 g applied topically to the infrascapular area of the back.

topical Diltiazem Hydrochloride 2% Cream

Vehicle Cream DRUG

0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.

Vehicle Cream

0.1% solution o sodium lauryl sulfate (SLS) DRUG

0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.

0.2% sodium lauryl sulfate (SLS)

Saline 0.9% DRUG

0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.

0.9% saline

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Are healthy males or females (to be confirmed by medical history)
• Are 18 years of age or older
• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes
• If a female of childbearing potential, have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at end of study (EOS)
• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events
• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema
• Complete a Medical Screening form as well as a Medical Personal History form
• Read, understand, and provide signed informed consent

You may not qualify if:

• Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history
• Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history)
• Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs)
• Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history)
• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction
• Are not willing to refrain from using systemic/topical analgesics such as aspirin (81 mg daily aspirin will be allowed), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to Day 1 and during the study (occasional use of acetaminophen will be permitted)
• Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to Day 1 and during the study
• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications
• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study
• Have psoriasis and/or active atopic dermatitis/eczema
• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child
• Have a known sensitivity to constituents present in the material being evaluated
• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site
• Have received treatment for any type of internal cancer within 5 years prior to study entry
• Have a history of, or are currently being treated for skin cancer

Sponsors & Collaborators

• Ventrus Biosciences, Inc: lead

Study Sites (1)

TKL Research

Paramus, New Jersey, 07652, United States

Location

MeSH Terms

Interventions

Diltiazem; Sodium Chloride

Intervention Hierarchy (Ancestors)

Benzazepines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Chlorides; Hydrochloric Acid; Chlorine Compounds; Inorganic Chemicals; Sodium Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: TRIPLE
• Who Masked: PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 26, 2013
• First Posted: March 29, 2013
• Study Start: March 1, 2013
• Primary Completion: July 1, 2013
• Study Completion: September 1, 2013
• Last Updated: August 21, 2013

Record last verified: 2013-07

Locations

US (1)